Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
Agios Pharmaceuticals, Inc. (the Company) held its Annual Meeting
of Stockholders on June13, 2017. The following is a summary of
the matters voted on at that meeting.
| 1. |
The Companys stockholders elected Dr.LewisC. Cantley, Ph.D., Mr.PaulJ. Clancy and Mr.IanT. Clark as class I directors, each to serve for a three-year term expiring at the 2020 Annual Meeting of Stockholders and until his successor has been duly elected and qualified. The results of the stockholders vote with respect to the election of such class I directors were as follows: |
| Votes For | Votes Withheld | Broker Non-Votes | ||||||||||
|
Dr.Lewis C. Cantley, Ph.D. |
31,734,840 | 550,548 | ||||||||||
|
Mr.PaulJ. Clancy |
32,100,022 | 185,366 | ||||||||||
|
Mr.IanT. Clark |
31,245,540 | 1,039,848 |
| 2. |
The Companys stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders non-binding, advisory vote with respect to compensation paid to the Companys named executive officers were as follows: |
|
Votes For |
Votes Against |
Votes Abstaining |
Broker Non-Votes |
|||
|
26,261,131 |
6,000,355 | 23,902 |
About Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. The lead product candidate in its RGD programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Its AG-221 is an orally available, selective, inhibitor of the mutated IDH2 protein indicated for the treatment of patients with cancers. Its AG-120 is an orally available, selective, inhibitor of the mutated isocitrate dehydrogenase (IDH1) protein for the treatment of patients with cancers. AG-881 is an orally available, selective, brain-penetrant, pan-IDH mutant inhibitor.
